Evidence map›Paper›PMID 26393654›Full record

ArticleGenes2015

Heterogeneous DNA Methylation Patterns in the GSTP1 Promoter Lead to Discordant Results between Assay Technologies and Impede Its Implementation as Epigenetic Biomarkers in Breast Cancer.

Grethe I Grenaker Alnaes, Jo Anders Ronneberg, Vessela N Kristensen, Jörg Tost

Open access · goldAbstract read
In one paragraph

Article in Genes, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Enhanced-Bio-protocol · 2019
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Grethe I Grenaker AlnaesDepartment of Cancer genetics, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Oslo 0310, Norway. Grethe.I.Grenaker.Alnas@rr-research.no.
Jo Anders RonnebergDepartment of Cancer genetics, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Oslo 0310, Norway. Jo.Anders.Ronneberg@gmail.com.
Vessela N KristensenDepartment of Cancer genetics, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Oslo 0310, Norway. v.n.kristensen@medisin.uio.no.
Jörg TostLaboratory for Epigenetics and Environment, Centre National de Génotypage, CEA-Institut de Génomique, Evry 91000, France. tost@cng.fr.
Oslo University Hospital · NOGenoscope · FRUniversity of Oslo · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Altered DNA methylation patterns are found in many diseases, particularly in cancer, where the analysis of DNA methylation holds the promise to provide diagnostic, prognostic and predictive information of great clinical value. Methylation of the promoter-associated CpG island of GSTP1 occurs in many hormone-sensitive cancers, has been shown to be a biomarker for the early detection of cancerous lesions and has been associated with important clinical parameters, such as survival and response to treatment. In the current manuscript, we assessed the performance of several widely-used sodium bisulfite conversion-dependent methods (methylation-specific PCR, MethyLight, pyrosequencing and MALDI mass-spectrometry) for the analysis of DNA methylation patterns in the GSTP1 promoter. We observed large discordances between the results obtained by the different technologies. Cloning and sequencing of the investigated region resolved single-molecule DNA methylation patterns and identified heterogeneous DNA methylation patterns as the underlying cause of the differences. Heterogeneous DNA methylation patterns in the GSTP1 promoter constitute a major obstacle to the implementation of DNA methylation-based analysis of GSTP1 and might explain some of the contradictory findings in the analysis of the significance of GSTP1 promoter methylation in breast cancer.

Indexed as

biomarkerbreast cancerDNA methylationGSTP1heterogeneitymass spectrometrymethodMethyLightMSPpyrosequencing

Identifiers

PMID26393654
PMCPMC4584334
OpenAlexW1904482722

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.